✦ LIBER ✦

537 - A phase II study of topotecan given as a continuous 21-day infusion every 28 days in platinum pre-treated ovarian carcinoma

✍ Scribed by S. Johnson; L. Pyle; K. King; M. Gore

Book ID: 117664785
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 261 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85053-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of topotecan administer

A phase II study of topotecan administered intravenously as 5 daily infusions every 21 days to women with refractory epithelial ovarian carcinoma

✍ Kudelka, A.; Edwards, C.; Freedman, R.; Wallin, B.; Hord, M.; Howell, E.; Harper 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 178 KB

Phase II evaluation of three-day topotec

Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study

✍ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a

Phase II trial of topotecan as a 21-day

Phase II trial of topotecan as a 21-day continuous infusion in patients with advanced or metastatic adenocarcinoma of the pancreas

✍ J.P Stevenson; R.M Scher; R Kosierowski; S.C Fox; M Simmonds; K.-S Yao; F Green; 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Phase I and Pharmacologic Study of the H

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

✍ Alison J. Davis; Karen A. Gelmon; Lillian L. Siu; Malcolm J. Moore; Carolyn D. B 📂 Article 📅 2003 🏛 Springer US 🌐 English ⚖ 142 KB

An open-label, single-arm Phase II study

An open-label, single-arm Phase II study of intravenous weekly (Days 1 and 8) topotecan in combination with carboplatin (Day 1) every 21 days as second-line therapy in patients with platinum-sensitive relapsed ovarian cancer

✍ Peter G. Rose; Bradley J. Monk; Diane Provencher; Jean Hartney; Philippe Legenne 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Phase I clinical and pharmacokinetic stu

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

✍ C Terret; S Zanetta; H Roché; J.H.M Schellens; M.N Faber; J Wanders; M Ravic; J. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 218 KB